Targeting the Serine Pathway: A Promising Approach against Tuberculosis?

Area of Science:

• Microbiology
• Drug Discovery
• Biochemistry

Background:

• Tuberculosis remains a leading infectious cause of death globally.
• Emerging drug-resistant tuberculosis strains necessitate novel therapeutic strategies.
• Current drug development pipeline for tuberculosis is limited, with some candidates already showing resistance.

Purpose of the Study:

• To provide an overview of current tuberculosis treatment options.
• To highlight the serine production pathway as a promising target for new drug discovery.
• To guide the design of novel inhibitors for essential enzymes in this pathway.

Main Methods:

• Review of current tuberculosis chemotherapy and drug resistance.
• Analysis of the serine production pathway, including enzymes SerA1, SerC, and SerB2.
• Examination of enzyme crystal structures and regulatory domains.
• Discussion of sequence alignment strategies for selective inhibition.
• Literature review of existing inhibitors, particularly for SerB2.

Main Results:

• The serine production pathway involves three essential enzymes (SerA1, SerC, SerB2) crucial for bacterial growth.
• These enzymes represent viable therapeutic drug targets.
• Crystal structures reveal key regulatory domains for potential inhibition.
• Sequence alignment can identify critical residues for selective drug targeting.
• Currently, only SerB2 inhibitors are documented, but human enzyme inhibitors offer a starting point.

Conclusions:

• The serine production pathway offers a promising avenue for developing new anti-tuberculosis drugs.
• Targeting SerA1, SerC, and SerB2, individually or in combination, could overcome existing resistance mechanisms.
• Further research into selective inhibitors, potentially adapted from human enzyme inhibitors, is warranted.